Repeated short periods of regional myocardial ischemia: effect on local function and high energy phosphate levels
- PMID: 3778416
- DOI: 10.1007/BF01907457
Repeated short periods of regional myocardial ischemia: effect on local function and high energy phosphate levels
Abstract
The effect of recurrent periods of ischemia on the myocardium was investigated in 15 open-chest dogs. Ischemia was produced by 3 minutes of proximal occlusion of the left anterior descending coronary artery. Each occlusion was followed by reperfusion of 3 minutes duration. Forty occlusions with a total of 120 minutes of ischemia were performed, and regional function (sonomicrometry) as well as high energy phosphates (needle biopsies) were determined at the end of the 5th, 20th, and 40th period of ischemia and reperfusion. The first periods of ischemia had a cumulative effect both on regional postischemic function (44% and 59% respectively of preischemic control after 20 occlusions) and on the ATP content, but with increasing number of occlusions the additive effects became smaller (ATP reduction/mumol/g w w/per occlusion). The ATP breakdown per occlusion was diminished with increasing number of periods of ischemia, and no significant adenosine was measured in the ischemic myocardium. Higher than normal postischemic creatine phosphate levels (9.1 mumol/g w w at the 40th reperfusion vs. 6.7 mumol/g w w control) indicated a functioning oxidative phosphorylation in the presence of an ATP utilization problem at the sarcomere level, because indicators of the cellular energy level (energy charge, free energy change of ATP hydrolysis) quickly normalized during reperfusion. Stunned myocardium is therefore not a problem of energy supply but rather of energy utilization. Reduced ATP utilization and regional dysfunction are the expressions of the same cellular defect which resides either in the ATP-splitting contractile apparatus or in the electromechanical coupling. Contractile dysfunction during reperfusion protects the heart against subsequent periods of ischemia because ATP turnover is reduced.
Similar articles
-
Effects of recurrent ischemia on myocardial high energy phosphate content in canine hearts.Basic Res Cardiol. 1984 Jul-Aug;79(4):469-78. doi: 10.1007/BF01908148. Basic Res Cardiol. 1984. PMID: 6487240
-
Inorganic phosphate content and free energy change of ATP hydrolysis in regional short-term hibernating myocardium.Cardiovasc Res. 1998 Aug;39(2):318-26. doi: 10.1016/s0008-6363(98)00086-8. Cardiovasc Res. 1998. PMID: 9798517
-
In vivo alterations of high-energy phosphates and intracellular pH during reversible ischemia in pigs: a 31P magnetic resonance spectroscopy study.Am Heart J. 1988 Sep;116(3):701-8. doi: 10.1016/0002-8703(88)90327-4. Am Heart J. 1988. PMID: 3414485
-
Effect of verapamil on postischemic "stunned" myocardium: importance of the timing of treatment.J Am Coll Cardiol. 1988 Mar;11(3):614-23. doi: 10.1016/0735-1097(88)91540-9. J Am Coll Cardiol. 1988. PMID: 3278036 Review.
-
Time course and mechanisms of contractile dysfunction during acute myocardial ischemia.Circulation. 1993 May;87(5 Suppl):IV35-42. Circulation. 1993. PMID: 8485832 Review.
Cited by
-
Myocardial stunning and hibernation revisited.Nat Rev Cardiol. 2021 Jul;18(7):522-536. doi: 10.1038/s41569-021-00506-7. Epub 2021 Feb 2. Nat Rev Cardiol. 2021. PMID: 33531698 Review.
-
The early and late phases of preconditioning against myocardial stunning and the essential role of oxyradicals in the late phase: an overview.Basic Res Cardiol. 1996 Jan-Feb;91(1):57-63. doi: 10.1007/BF00788866. Basic Res Cardiol. 1996. PMID: 8660262 Review. No abstract available.
-
Preconditioning myocardium with ischemia.Cardiovasc Drugs Ther. 1991 Oct;5(5):933-8. doi: 10.1007/BF00053555. Cardiovasc Drugs Ther. 1991. PMID: 1756140 Review.
-
Salvage of jeopardized myocardium by ischemic preconditioning: is the quest over?Mol Cell Biochem. 1996 Jul-Aug;160-161:209-15. doi: 10.1007/BF00240051. Mol Cell Biochem. 1996. PMID: 8901475 Review.
-
Time course of myocardial necrosis.Cardiovasc Drugs Ther. 1988 May;2(1):17-25. doi: 10.1007/BF00054248. Cardiovasc Drugs Ther. 1988. PMID: 3154690 Review.